Rain Therapeutics Inc. announced the appointments of several industry veterans to the leadership team, including: Nora Ku, MD, Vice President of Clinical Development, joining from Loxo Oncology at Lilly; Buenaflor (Flor) Nicolas, MPH, Vice President, Head of Global Drug Safety and Pharmacovigilance, joining from Gilead Sciences Inc.; Tina Kim-Hafken, MS, Vice President and Head of Global Regulatory Affairs, joining from Seagen Inc.; and Steve Flint, SHRM, MBA, Vice President of People &Culture, joining from AltruBio Inc. Additionally, Rain announced that John Maraganore, Ph.D., former founding CEO of Alnylam and biotechnology industry veteran, has served as a Special Advisor to Rain's Chief Executive Officer (CEO), Avanish Vellanki, and the leadership team since March 2021. Ku served as Vice President of Medical at Loxo/Lilly. Previously, Dr. Ku was Consultant and Senior Medical Director at DAVA Oncology following several years in various practice settings as a clinical investigator.

After earning her M.D. from the University of California Los Angeles (UCLA), Dr. Ku completed her internship and residency in internal medicine at the University of Texas, Southwestern Medical Center, and fellowship in hematology and medical oncology at UCLA.